Gilead Sciences

Corporate

Biopharmaceutical company focused on developing and commercializing antiviral drugs and therapies.

Profile

Founded
1987
Headquarters
Foster City, US
Investments
1
Companies
1

Capital

Total Deployed
$75M
Lead Rounds
0
Website
www.gilead.com

Portfolio

1 company
Pardes Biosciences $127M
Acquired Carlsbad, US

Clinical-stage biopharmaceutical company that developed novel oral antiviral therapeutics targeting COVID-19. Went public via SPAC merger in 2021 before being acquired by MediPacific (a Foresite Capital affiliate) in 2023 after its lead candidate failed Phase 2 trials.

Investment data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.